What the intake form skips: undiagnosed diabetes and implant failure

Disclosure. Dr. Maloney has no commercial relationship with any clinic, marketplace, manufacturer, or industry body referenced in this piece. She did not receive payment, travel, accommodation, equipment, or any other consideration in connection with this piece. The publication’s standing disclosures (default: none) are documented at /disclosures/. Last reviewed: 2026-06-08.

This is the first piece in the What the Intake Form Skips series, which examines the systemic medical conditions that are under-screened in dental tourism intake processes and that have documented, quantifiable effects on implant outcomes. One condition per issue.

The dental tourism intake form asks whether you have diabetes. You do not know that you do. You tick “no.” Three months after your full-arch reconstruction, your implants begin failing.

This sequence happens. The magnitude of the undiagnosed diabetes problem in the source markets for dental tourism is not trivial. The Australian Bureau of Statistics estimates that roughly 1.3 million Australians had undiagnosed diabetes as of 2022, and a further 2 to 3 million are in a prediabetic state. Comparable estimates exist for the US, UK, Canada, and New Zealand. These are patients with impaired glycaemic control who do not know it, and who will not spontaneously disclose it on any intake form.

Why glycaemic control matters for osseointegration

The mechanism by which uncontrolled diabetes impairs implant osseointegration is not theoretical. It operates through several well-documented pathways.

Impaired wound healing. Hyperglycaemia impairs neutrophil function, reduces phagocytic capacity, and compromises the inflammatory response needed for normal wound healing. The early healing phase after implant placement — the period when the body must clear surgical debris, prevent infection, and begin bone apposition to the implant surface — is the period most directly affected.

Microvascular compromise. Chronic hyperglycaemia causes microvascular dysfunction through advanced glycation end-products and nitric oxide pathway impairment. Bone is heavily dependent on blood supply for both nutrient delivery and waste removal. Compromised microvascular supply to the periimplant bone reduces the quality of the osseointegrating environment.

Increased infection susceptibility. The surgical wound after implant placement is exposed to the oral cavity, which is not a sterile environment. Patients with uncontrolled diabetes have impaired immune surveillance against oral pathogens. The risk of post-operative infection, peri-implantitis, and early implant failure is elevated.

Delayed bone remodelling. Bone remodelling around an implant surface involves osteoclast and osteoblast activity. Both are affected by hyperglycaemia. Poorly controlled diabetes shifts the remodelling balance toward net bone loss, which has direct implications for long-term implant stability.

What the evidence shows

Multiple systematic reviews have examined implant failure rates in patients with diabetes versus controls. The consistent finding is that well-controlled diabetes (HbA1c below 7%) does not dramatically increase implant failure rates compared to non-diabetic controls. Poorly controlled diabetes (HbA1c above 8%, and especially above 9%) is associated with higher failure rates, more peri-implantitis, and more post-operative complications.

The specific studies vary in sample size, definition of failure, and follow-up duration. What they agree on is the direction and the threshold. The HbA1c cut-off of 7% is not arbitrary. It represents the clinical consensus on what level of glycaemic control allows elective surgical procedures to proceed safely.

The published HbA1c-before-implant literature (including a 2022 systematic review in the literature, covering multiple cohorts) consistently supports pre-operative HbA1c testing as a meaningful predictor of implant outcomes in high-risk populations.

The external validity question for dental tourism patients: these studies generally enrolled patients in institutional settings with proper pre-operative workup. The dental tourism patient self-selecting for the cheapest full-arch quote is not necessarily the same patient who had a GP-ordered HbA1c in the six months before surgery. Whether their outcomes match the controlled-diabetes or uncontrolled-diabetes group depends on information that nobody bothered to capture.

Why the dental tourism intake process does not catch this

The dental tourism booking funnel is designed to convert enquiries to deposits. A requirement for an HbA1c result before confirming a booking adds friction to that conversion and creates a delay that may cause the patient to book elsewhere.

This is not an accusation against any specific clinic. It is a description of the incentive structure. Clinics that operate at high volume with pre-fixed departure schedules do not have a natural mechanism for inserting a blood test with a 48-hour turnaround into a booking process that is often finalised weeks or months in advance. The clinic expects the patient to have completed their own pre-operative workup. The patient does not know they need one.

The home GP, who might normally identify this risk, is not involved in the dental tourism decision. The patient did not tell their GP they were having implant surgery abroad. The GP’s chronic disease management programme may have identified the patient as prediabetic, but that conversation has not been bridged to the dental treatment plan.

The result is a gap. The patient goes to the clinic with undiagnosed impaired glycaemic control. The clinic places implants. Nobody knows the patient’s HbA1c. The implants may fail. If they fail, the cause may not be identified without a retrospective blood test that nobody ordered.

What an adequate pre-departure screening looks like

Before proceeding with implant surgery through any dental tourism programme, a responsible pre-operative minimum includes:

HbA1c test. Ordered through your home GP or practice nurse. Results in 24 to 48 hours. If you are over 40, overweight, have a first-degree relative with type 2 diabetes, or have ever been told your blood glucose is borderline, this test is worth doing before any major dental surgery regardless of where it occurs.

If the result is below 7%: Your glycaemic control is adequate. Tell the treating clinic the result.

If the result is 7 to 8%: This is the contested zone. Your GP should be involved in a decision about whether elective major surgery is appropriate at this level of control or whether a period of optimisation first makes more sense.

If the result is above 8%: Do not proceed with elective full-arch implant surgery until you have worked with your GP or endocrinologist to improve glycaemic control. The evidence for this recommendation is not ambiguous.

The test costs under AUD 35. The implant surgery costs, at a minimum, several thousand dollars. The cost-benefit calculation is not complicated.

The falsification condition

I would revise this assessment if a large registry study (N greater than 2,000, multi-centre, dental tourism context) showed implant failure rates in patients with unscreened HbA1c were not different from screened populations with known glycaemic control. That study does not exist. Until it does, the mechanism and the evidence are aligned: uncontrolled diabetes impairs osseointegration, undiagnosed diabetes is common in the source markets for dental tourism, and the intake form does not catch it.

Related reading: What the intake form skips: bisphosphonates and MRONJ · What the intake form skips: smoking and implant failure · Fit to fly after implant surgery · Root canal abroad: who reads the recall radiograph · Peri-implantitis: bone loss cascade